SANA241220C15000
- 0.00
- 0.000.00%
Sana Biotechnology Newsroom
Express News | Sana Biotechnology Inc - Expect to Report Initial Clinical Data in 2025 in Gleam Trial for Sc291 in B-Cell Mediated Autoimmune Diseases
Express News | Sana Biotechnology Announces FDA Fast Track Designation For SC291 In Relapsed/Refractory Systemic Lupus Erythematosus
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
Sana Biotechnology to Present at December 2024 Investor Conferences
Flagship Pioneering Announces Two New Agreements With Ampersand Biomedicines and Montai Therapeutics Under Its Strategic Partnership With Pfizer
Down -24.69% in 4 Weeks, Here's Why Sana (SANA) Looks Ripe for a Turnaround
Sana Biotechnology Analyst Ratings
JMP Securities Maintains Sana Biotechnology(SANA.US) With Hold Rating
TD Cowen Maintains Sana Biotechnology(SANA.US) With Hold Rating
Sana Biotechnology: Hold Rating Amid Fiscal Caution and Strategic Priorities
H.C. Wainwright Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $8
Sana Biotechnology's Strategic Shift to Autoimmune Diseases Drives Buy Rating Despite Lowered Price Target
Sana Biotechnology | 10-Q: Q3 2024 Earnings Report
Sana Biotechnology | 8-K: Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
Sana Biotechnology 3Q Research and Development Expenses $53.2M >SANA
Express News | Sana Biotechnology Q3 EPS USD -0.25
Express News | Sana Biotechnology Q3 Adjusted EPS USD -0.27 Vs. IBES Estimate USD -0.25
Express News | Sana Biotechnology Q3 Adjusted Net Income USD -64.658 Million Vs. IBES Estimate USD -59.9 Million
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
Press Release: Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates